Price Alert

Legend Biotech Corporatio... (LEGN)

NASDAQ: LEGN · Real-Time Price · USD

37.27

-0.44 (-1.17%)

At close: Aug 15, 2025, 2:32 PM

Legend Biotech Statistics

Share Statistics

Legend Biotech has 92.01M shares outstanding. The number of shares has increased by 0.47% in one year.

Shares Outstanding	92.01M
Shares Change (YoY)	0.47%
Shares Change (QoQ)	0.21%
Owned by Institutions (%)	46.72%
Shares Floating	90.69M
Failed to Deliver (FTD) Shares	3,357
FTD / Avg. Volume	0.19%

Short Selling Information

The latest short interest is 8.39M, so 4.57% of the outstanding shares have been sold short.

Short Interest	8.39M
Short % of Shares Out	4.57%
Short % of Float	8.73%
Short Ratio (days to cover)	6.35

Valuation Ratios

The PE ratio is -16.81 and the forward PE ratio is 57.89. Legend Biotech's PEG ratio is 0.25.

PE Ratio	-16.81
Forward PE	57.89
PS Ratio	4.74
Forward PS	2.2
PB Ratio	2.86
P/FCF Ratio	-18.81
PEG Ratio	0.25

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Legend Biotech.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.62, with a Debt / Equity ratio of 0.34.

Current Ratio	4.62
Quick Ratio	4.54
Debt / Equity	0.34
Debt / EBITDA	-3.1
Debt / FCF	-2.22
Interest Coverage	-14.03

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$241.25K
Profits Per Employee	$-68.09K
Employee Count	2,600
Asset Turnover	0.38
Inventory Turnover	9.81

Taxes

Income Tax	18.89M
Effective Tax Rate	-11.95%

Stock Price Statistics

The stock price has increased by -35.59% in the last 52 weeks. The beta is 0.26, so Legend Biotech's price volatility has been higher than the market average.

Beta	0.26
52-Week Price Change	-35.59%
50-Day Moving Average	37.01
200-Day Moving Average	36.29
Relative Strength Index (RSI)	39.47
Average Volume (20 Days)	1,721,803

Income Statement

In the last 12 months, Legend Biotech had revenue of 627.24M and earned -177.03M in profits. Earnings per share was -1.94.

Revenue	627.24M
Gross Profit	392.66M
Operating Income	-303.24M
Net Income	-177.03M
EBITDA	-113.16M
EBIT	-136.52M
Earnings Per Share (EPS)	-1.94

Full Income Statement

Balance Sheet

The company has 286.75M in cash and 350.6M in debt, giving a net cash position of -63.85M.

Cash & Cash Equivalents	286.75M
Total Debt	350.6M
Net Cash	-63.85M
Retained Earnings	-1.66B
Total Assets	1.62B
Working Capital	984.42M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -144.03M and capital expenditures -14.11M, giving a free cash flow of -158.14M.

Operating Cash Flow	-144.03M
Capital Expenditures	-14.11M
Free Cash Flow	-158.14M
FCF Per Share	-1.73

Full Cash Flow Statement

Margins

Gross margin is 62.6%, with operating and profit margins of -48.35% and -28.22%.

Gross Margin	62.6%
Operating Margin	-48.35%
Pretax Margin	-25.21%
Profit Margin	-28.22%
EBITDA Margin	-18.04%
EBIT Margin	-48.35%
FCF Margin	-25.21%

Dividends & Yields

LEGN does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for LEGN is $78, which is 115.3% higher than the current price. The consensus rating is "Buy".

Price Target	$78
Price Target Difference	115.3%
Analyst Consensus	Buy
Analyst Count	10

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	2.71
Piotroski F-Score	2